Latest news and upcoming events

26 May 2021

Ysios Capital closes its third fund at €216 million ($260 million)

Upcoming events
  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

  • Biotech Europe Forum 2021
    7 October – 8 October 2021,

  • Venture Capital Forum 2021
    13 October – 14 October 2021,

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

Ysios Capital co-leads EUR 51 million Series A financing in Adcendo.

CorWave presents an unprecedented chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation

This breakthrough is an important step towards the finalization of the development of CorWave's revolutionary technology.

Synendos Therapeutics Expands Series A to CHF 24 million with new investment

Ysios Capital joins existing syndicate of European investors.

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

Broadens SparingVision’s innovative genomic medicine pipeline to address both mid and late stages of rod-cone dystrophies with the added potential to combine both products.

Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform

Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity

Mirum Pharmaceuticals and Vivet Therapeutics enter into exclusive worldwide option and license agreement for Vivet’s gene therapy programs targeting PFIC

Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2.

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Overall results support the positive effects of leriglitazone on reducing the progression of cerebral lesions and myelopathy symptoms.

LAVA Therapeutics Announces Pricing of Initial Public Offering

Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be $100.5 million.

Aura Biosciences Announces Oversubscribed $80 Million Financing

Ysios Capital joins Aura Biosciences 80MUSD financing

AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial

Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication


Subscribe to our weekly newsletter for the latest
updates on life sciences investments.